Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
120.2 rhumatos / 100 000 hab. — département bien doté
4 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Médecin engagé dans la recherche académique — 4 publications référencées dans les bases scientifiques internationales.
Affiliations FR : Centre Hospitalier de La Rochelle
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Association of eating disorders and/or insulin omission with impaired glycaemic control in persons living with type 1 diabetes: cross-sectional analysis of the French SFDT1 study
2026ArticleBMJ Open
A nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events
2026ArticleDiabetes, Obesity and Metabolism
Musculoskeletal disorders in type 1 diabetes: Clinical phenotyping and associations with quality of life and glucose control - The French SFDT1 cohort study
2025ArticleDiabetes & Metabolism
Advanced Hybrid Closed Loop Algorithm Use in Type 1 Diabetes: The French MiniMed™ Glycemic Control and Quality of Life Study
2024ArticleDiabetes Therapy
The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19)
2022ArticleCardiovascular Diabetology
An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes
2022ArticlePatient Preference and Adherence
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
2021ArticleDiabetes & Metabolism
Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study
2020ArticleDiabetes Research and Clinical Practice
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL SAINT-LOUIS - LA ROCHELLE
R DU DR SCHWEITZER, 17019 LA ROCHELLE CEDEX 1
CARDIOCEAN - PUILBOREAU
LD LA TOURTILLIERE BP 26, 17138 PUILBOREAU
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Diabetes care · 2018
OBJECTIVE In patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. RESEARCH DESIGN AND METHODS A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20–50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day. RESULTS Glycated hemoglobin (HbA1c) decreased from 8.2% (66 mmol/mol) to 6.7% (50 mmol/mol) with IDegLira and from 8.2% (67 mmol/mol) to 6.7% (50 mmol/mol) with basal-bolus (estimated treatment difference [ETD] −0.02% [95% CI −0.16, 0.12]; −0.2 mmol/mol [95% CI −1.7, 1.3]), confirming IDegLira noninferiority versus basal-bolus (P < 0.0001). The number of severe or blood glucose–confirmed symptomatic hypoglycemia events was lower with IDegLira versus basal-bolus (risk ratio 0.39 [95% CI 0.29, 0.51]; rate ratio 0.11 [95% CI 0.08, 0.17]). Body weight decreased with IDegLira and increased with basal-bolus (ETD −3.6 kg [95% CI −4.2, −2.9]). Fasting plasma glucose reductions were similar; lunch, dinner, and bedtime self-monitored plasma glucose measurements were significantly lower with basal-bolus. Sixty-six percent of patients on IDegLira vs. 67.0% on basal-bolus achieved HbA1c <7.0% (53 mmol/mol). Total daily insulin dose was lower with IDegLira (40 units) than basal-bolus (84 units total; 52 units basal). CONCLUSIONS In patients with uncontrolled type 2 diabetes on IGlar U100 and metformin, IDegLira treatment elicited HbA1c reductions comparable to basal-bolus, with statistically superior lower hypoglycemia rates and weight loss versus weight gain.
Diabetes care · 2011
OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%). We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar) in insulin-naïve subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs. RESEARCH DESIGN AND METHODS In this 16-week, open-label trial, subjects (mean age 59.1 years, A1C 8.5%, BMI 30.3 kg/m2) were randomized to once-daily IDegAsp (n = 59), AF (n = 59), or IGlar (n = 60), all in combination with metformin. Insulin was administered before the evening meal and dose-titrated to a fasting plasma glucose (FPG) target of 4.0–6.0 mmol/L. RESULTS After 16 weeks, mean A1C decreased in all groups to comparable levels (IDegAsp: 7.0%; AF: 7.2%; IGlar: 7.1%). A similar proportion of subjects achieved A1C <7.0% without confirmed hypoglycemia in the last 4 weeks of treatment (IDegAsp: 51%; AF: 47%; IGlar: 50%). Mean 2-h postdinner plasma glucose increase was lower for IDegAsp (0.13 mmol/L) and AF (0.24 mmol/L) than IGlar (1.63 mmol/L), whereas mean FPG was similar (IDegAsp: 6.8 mmol/L; AF: 7.4 mmol/L; IGlar: 7.0 mmol/L). Hypoglycemia rates were lower for IDegAsp and IGlar than AF (1.2, 0.7, and 2.4 events/patient year). Nocturnal hypoglycemic events occurred rarely for IDegAsp (1 event) and IGlar (3 events) compared with AF (27 events). CONCLUSIONS In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control.
Diabetes research and clinical practice · 2020
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
La Revue de medecine interne · 1986 · English Abstract
Gouet D, Azaïs I, Maréchaud R, Alcalay M, et al.
Presse medicale (Paris, France : 1983) · 1983 · Case Reports
Gouet D, Touchard G, Thomas P, Alcalay M, et al.
Annales de medecine interne · 1983 · Case Reports
Gouet D, Rouffineau J, Marechaud R, Thomas P, et al.
La Revue de medecine interne · 1982 · Case Reports
Gouet D, Alcalay D, Thomas P, Alcalay M, et al.
PloS one · 2023 · Randomized Controlled Trial
Amadou C, Melki V, Allain J, Clavel S, et al.
Diabetes care · 2018 · Clinical Trial, Phase III
Billings LK, Doshi A, Gouet D, Oviedo A, et al.
Diabetes care · 2011 · Journal Article
Diabetes & metabolism · 2025 · Journal Article
Topalian N, Picard S, Riveline JP, Canha D, et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025 · Published Erratum
Kessler L, Thivolet C, Penfornis A, Gouet D, et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025 · Journal Article
Kessler L, Thivolet C, Penfornis A, Gouet D, et al.
Patient preference and adherence · 2022 · Journal Article
Reach G, Benarbia L, Benhamou PY, Delemer B, et al.
La Revue de medecine interne · 1983 · Case Reports
Gouet D, Maréchaud R, Neau JP, Touchard G, et al.
Revue du rhumatisme et des maladies osteo-articulaires · 1983 · Case Reports
Gouet D, Alcalay M, Briaud M, Touchard G, et al.
The Journal of rheumatology · 1986 · Case Reports
Gouet D, Marechaud R, Aucouturier P, Touchard G, et al.
Annales de medecine interne · 1983 · Case Reports
Gouet D, Cremault A, Rouffineau J, Lemaire M, et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020 · Journal Article
Gourdy P, Bahloul A, Boultif Z, Gouet D, et al.
Diabetes care · 2018 · Clinical Trial, Phase III
Billings LK, Doshi A, Gouet D, Oviedo A, et al.
Diabetes & metabolism · 2025 · Journal Article
Topalian N, Picard S, Riveline JP, Canha D, et al.
Diabetes research and clinical practice · 2020 · Journal Article
Suteau V, Saulnier PJ, Wargny M, Gonder-Frederick L, et al.
Presse medicale (Paris, France : 1983) · 1984 · Case Reports
Gouet D, Anquez M, Risse JF, Becq-Giraudon B
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300U/ml: The TRANSITION 2 Study
<strong>Article full text</strong><br> <br> The article associated with this content has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300U/ml: The TRANSITION 2 Study
<strong>Article full text</strong><br> <br> The article associated with this content has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Heise T, Tack CJ, Cuddihy R, Davidson J, et al.